Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors
- 16 November 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (109), 109ra115
- https://doi.org/10.1126/scitranslmed.3003021
Abstract
Chronic and recurrent urinary tract infections pose a serious medical problem because there are few effective treatment options. Patients with chronic urinary tract infections are commonly treated with long-term prophylactic antibiotics that promote the development of antibiotic-resistant forms of uropathogenic Escherichia coli (UPEC), further complicating treatment. We developed small–molecular weight compounds termed mannosides that specifically inhibit the FimH type 1 pilus lectin of UPEC, which mediates bacterial colonization, invasion, and formation of recalcitrant intracellular bacterial communities in the bladder epithelium. Here, we optimized these compounds for oral bioavailability and demonstrated their fast-acting efficacy in treating chronic urinary tract infections in a preclinical murine model. These compounds also prevented infection in vivo when given prophylactically and strongly potentiated the activity of the current standard of care therapy, trimethoprim-sulfamethoxazole, against clinically resistant PBC-1 UPEC bacteria. These compounds have therapeutic efficacy after oral administration for the treatment of established urinary tract infections in vivo. Their unique mechanism of action—targeting the pilus tip adhesin FimH—circumvents the conventional requirement for drug penetration of the outer membrane, minimizing the potential for the development of resistance. The small–molecular weight compounds described herein promise to provide substantial benefit to women suffering from chronic and recurrent urinary tract infections.This publication has 60 references indexed in Scilit:
- Cranberries vs Antibiotics to Prevent Urinary Tract InfectionsJAMA Internal Medicine, 2011
- Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbationProceedings of the National Academy of Sciences of the United States of America, 2010
- Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH AntagonistsJournal of Medicinal Chemistry, 2010
- Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose bindingProceedings of the National Academy of Sciences of the United States of America, 2009
- Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formationNature Chemical Biology, 2009
- TLR4-mediated expulsion of bacteria from infected bladder epithelial cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Adaptive mutations in the signal peptide of the type 1 fimbrial adhesin of uropathogenic Escherichia coliProceedings of the National Academy of Sciences of the United States of America, 2008
- TLR4-Initiated and cAMP-Mediated Abrogation of Bacterial Invasion of the BladderCell Host & Microbe, 2007
- Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tractProceedings of the National Academy of Sciences of the United States of America, 2006